Patents by Inventor Russell Z. Szmulewitz

Russell Z. Szmulewitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING CASTRATION-RESISTANT PROSTATE CANCER WITH GLUCOCORTICOID RECEPTOR ANTAGONISTS AND ANTI-ANDROGEN RECEPTOR THERAPY AND ANTI-ANDROGEN RECEPTOR THERAPY
    Publication number: 20230218634
    Abstract: Embodiments of the invention are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Application
    Filed: December 23, 2022
    Publication date: July 13, 2023
    Applicant: University of Chicago
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen
  • Methods of treating castration-resistant prostate cancer with glucocorticoid receptor antagonists and anti-androgen receptor therapy
    Patent number: 11564932
    Abstract: Embodiments of the invention are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: January 31, 2023
    Assignee: The University of Chicago
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen
  • METHODS OF TREATING CASTRATION-RESISTANT PROSTATE CANCER WITH GLUCOCORTICOID RECEPTOR ANTAGONISTS
    Publication number: 20200330482
    Abstract: Embodiments of the invention are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Application
    Filed: June 26, 2020
    Publication date: October 22, 2020
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen
  • Methods of treating castration-resistant prostate cancer with glucocorticoid receptor antagonists after anticancer therapy
    Patent number: 10729699
    Abstract: Embodiments of the invention are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: August 4, 2020
    Assignee: The University of Chicago
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen
  • METHODS OF TREATING CASTRATION-RESISTANT PROSTATE CANCER WITH GLUCOCORTICOID RECEPTOR ANTAGONISTS
    Publication number: 20190255069
    Abstract: Embodiments of the invention are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Application
    Filed: April 3, 2019
    Publication date: August 22, 2019
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen
  • Methods of treating castration-resistant prostate cancer with glucocorticoid receptor antagonists
    Patent number: 10300076
    Abstract: Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: May 28, 2019
    Assignee: The University of Chicago
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen
  • METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISM AND PROST A TE CANCER
    Publication number: 20180036318
    Abstract: Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Application
    Filed: September 14, 2017
    Publication date: February 8, 2018
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen
  • Method of treatment for prostate cancer with androgen receptor antagonists and glucocorticoid receptor antagonists
    Patent number: 9801893
    Abstract: Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: October 31, 2017
    Assignee: The University of Chicago
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen
  • Methods and Compositions Related to Glucocorticoid Receptor Antagonism and Prostate Cancer
    Publication number: 20160151388
    Abstract: Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Application
    Filed: February 2, 2016
    Publication date: June 2, 2016
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen
  • Method of treatment of prostate cancer with androgen receptor and glucocorticoid receptor antagonists
    Patent number: 9289436
    Abstract: Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: March 22, 2016
    Assignee: The University of Chicago
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen
  • Methods and Compositions Related to Glucocorticoid Receptor Antagonism and Prostate Cancer
    Publication number: 20150010503
    Abstract: Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Application
    Filed: February 21, 2013
    Publication date: January 8, 2015
    Applicant: The University of Chicago
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen